EyePoint (STU:PV3B) Interest Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:PV3B EyePoint Inc STU:PV3B
38 GF Score
Price €13.00
GF Value €0.96
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is EyePoint Interest Received?

Interest Received only applicable to companies reporting Cash Flow from Operations in direct method.

STU:PV3B
38GF Score
EyePoint Inc STU:PV3B
Interest Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is EyePoint (STU:PV3B) Overvalued in 2026?

Based on GuruFocus' analysis, EyePoint stock appears to be overvalued. The current stock price of €13.00 is trading 1254.2% above its estimated GF Value™ of €0.96. GuruFocus considers EyePoint to be Significantly Overvalued.

Key valuation signals for STU:PV3B:

  • Interest Received:
  • GF Value™: €0.96 vs. price of €13.00 (1254.2% above fair value)
  • GF Score™: 38/100 with 6 warning signs

No single metric tells the full story. See the STU:PV3B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


EyePoint Business Description

Other Exchanges EYPT:USA
Address 480 Pleasant Street, Suite C-400, Watertown, MA, USA, 02472
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
38GF Score

Get the complete analysis for STU:PV3B

Interest Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€13.00
Price
€0.96
GF Value